ClinicalTrials.gg
Active, not recruitingNCT04246047DREAMM 7Updated Nov 13, 2026Results posted

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

A Phase 3 interventional study of Belantamab mafodotin and Daratumumab in Multiple Myeloma, sponsored by GlaxoSmithKline. Active, not recruiting at 143 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Updated Nov 13, 2026First sites in 7 new countriesPosted results revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
494
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.

Enrollment
3rd of 49
494 · median 50
Started
2020
with 5 others
Phase 3
9 of 49
2 open now
Primary completion
2023-10
later than 1 of 34 live
Registered
8th of 49
by date
Lead sponsor
24 of 49
GlaxoSmithKline

Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 3rd largest by enrollment, is one of 6 that started in 2020, is one of 9 in phase 3, reaches primary completion later than 1 of the 34 other live ones, and was the 8th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About belantamab mafodotin

belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing belantamab mafodotin in Multiple Myeloma, or all of them as a file.
02

Study summary

This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Global Cohort
  • Belantamab mafodotin
  • Relapsed/refractory multiple myeloma
  • Daratumumab
  • Bortezomib
  • Dexamethasone
  • Multiple Myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.
  • Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy.
  • (ECOG) performance status of 0 to 2.
  • Must have at least 1 aspect of , defined as one of the following;

    1. Urine M-protein excretion >=200 mg per 24-hour, or
    2. Serum M-protein concentration >=0.5 grams per deciliter (g/dL), or
    3. Serum free light chain (FLC) assay: involved FLC level >=10 mg per dL (>=100 mg per liter) and an abnormal serum free light chain ratio (\<0.26 or >1.65).
  • All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [] version 5.0) must be \<=Grade 1 at the time of enrollment, except for alopecia.
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Intolerant to daratumumab.
  • to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).
  • Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m\^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed.
  • Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.
  • Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.
  • Prior allogenic stem cell transplant.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior .
  • Corneal epithelial disease.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
494 participants (actual)

Study arms

  • Experimental
    Belantamab mafodotin and Bortezomib plus Dexamethasone (Arm A)

    Drug: Belantamab mafodotin · Drug: Bortezomib · Drug: Dexamethasone

  • Active comparator
    Daratumumab and Bortezomib plus Dexamethasone (Arm B)

    Drug: Daratumumab · Drug: Bortezomib · Drug: Dexamethasone

Interventions

  • Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate

  • Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody

  • Proteasome Inhibitor

  • Synthetic glucocorticoid with anti-tumor activity

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5 grams per deciliter {g/dL}\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200 milligrams per 24 hours {mg/24h}\]; participants without measurable serum \& urine M-protein levels, difference between involved \& uninvolved serum free light chains (sFLC) levels \[absolute increase \>10mg/dL\]; appearance of new lesion,\>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 centimeter (cm) in short axis.

    Time frame: Up to approximately 41 months

Secondary outcomes

  1. Complete Response Rate (CRR)

    CRR is defined as percentage of participants with a confirmed complete response or better.

    Time frame: Up to 73 months

  2. Overall Response Rate (ORR)

    ORR is defined as percentage of participants with a confirmed partial response or better.

    Time frame: Up to 73 months

  3. Clinical Benefit Rate (CBR)

    CBR is defined as percentage of participants with a confirmed minimal response (MR) or better

    Time frame: Up to 73 months

  4. Duration of Response (DoR)

    DOR is defined as time from first documented evidence of partial response or better until first documented progression or death, whichever occurs first.

    Time frame: Up to 73 months

  5. Time to Response (TTR)

    TTR is defined as time from the date of randomization and the first documented evidence of response (PR or better) among participants who achieve partial response or better.

    Time frame: Up to 73 months

  6. Time to Progression (TTP)

    TTP is defined as time from the date of randomization until the earliest date of documented date of disease progression or death, whichever occurs first.

    Time frame: Up to 73 months

  7. Overall Survival (OS)

    OS is defined as time from the date of randomization until the date of death due to any cause.

    Time frame: Up to 73 months

  8. Progression-free Survival on Subsequent Line of Therapy (PFS2)

    Progression-free survival on subsequent line of therapy is defined as time from randomization to disease progression after initiation of new anti-myeloma therapy or death from any cause, whichever occurs first. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier.

    Time frame: Up to 73 months

  9. Minimal Residual Disease (MRD) Negativity Rate

    Minimal Residual Disease (MRD) negativity rate is defined as the percentage of participants who are MRD negative status by next generation sequencing (NGS).

    Time frame: Up to 73 months

  10. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.

    Time frame: Up to 73 months

  11. Number of Participants With Clinically Significant Changes in Hematology Parameters

    Blood samples will be collected for the analysis of hematology parameters.

    Time frame: Up to 73 months

  12. Number of Participants With Clinically Significant Changes in Clinical Chemistry

    Blood samples will be collected for the analysis of clinical chemistry parameters.

    Time frame: Up to 73 months

  13. Number of Participants With Clinically Significant Changes in Urine Dipstick

    Urine samples will be collected for the urine dipstick analysis.

    Time frame: Up to 73 months

  14. Number of Participants With Abnormal Ocular Findings on Ophthalmic Examination

    Time frame: Up to 73 months

  15. Plasma Concentrations of Belantamab Mafodotin (Total Antibody) at Indicated Time Points

    Blood samples will be collected for PK analysis of belantamab mafodotin.

    Time frame: Up to 73 months

  16. Plasma Concentrations of Belantamab Mafodotin (ADC) at Indicated Time Points

    Blood samples will be collected for PK analysis of belantamab mafodotin.

    Time frame: Up to 73 months

  17. Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF) at Indicated Time Points

    Blood samples will be collected for PK analysis of belantamab mafodotin.

    Time frame: Up to 73 months

  18. Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin

    Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers.

    Time frame: Up to 73 months

  19. Titers of ADAs Against Belantamab Mafodotin

    Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be to be further tested in screening assay, and positive samples will be further to be characterized for antibody titers.

    Time frame: Up to 73 months

  20. Number of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)

    The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE.

    Time frame: Up to 73 months

  21. Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by EuropeanOrganization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)

    The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning \[PF\], role functioning \[RF\], cognitive functioning \[CF\], emotional functioning \[EF\] and social functioning \[SF\]), three symptom scales (fatigue, pain and nausea/vomiting \[N/V\]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss \[AL\] and financial difficulties \[FD\]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Up to 73 months

  22. Change From Baseline in HRQoL as Measured by EORTC IL52

    The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score represents a high/healthy level of functioning.

    Time frame: Up to 73 months

07

Results

Posted Oct 24, 2024

Participant flow

Participant flow — Overall Study
MilestoneBelantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)Daratumumab + Bor + Dex
Started243251
Safety population242246
Completed00
Not completed243251
Withdrew: Death5077
Withdrew: Lost to follow-up13
Withdrew: Physician decision410
Withdrew: Withdrawal by subject1926
Withdrew: Ongoing169135

Outcome measures

PrimaryProgression-free Survival (PFS)

PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD= increase of \>=25% from lowest value in \>=1 of following (serum M-protein \[absolute increase \>=0.5 grams per deciliter {g/dL}\]; serum M-protein increase \>=1g/dL \[when lowest M-protein \>=5g/dL\]; urine M-protein \[absolute increase \>=200 milligrams per 24 hours {mg/24h}\]; participants without measurable serum \& urine M-protein levels, difference between involved \& uninvolved serum free light chains (sFLC) levels \[absolute increase \>10mg/dL\]; appearance of new lesion,\>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of \>1 lesion, or \>=50% increase in longest diameter of previous lesion \>1 centimeter (cm) in short axis.

Time frame:
Up to approximately 41 months
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsBelantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)Daratumumab + Bor + Dex
Progression-free Survival (PFS)36.6 (28.4 to NA)13.4 (11.1 to 17.5)
Statistical analysis
  • Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) vs Daratumumab + Bor + Dex · one-sided stratified log-rank · p = <0.00001 · Hazard ratio (hr): 0.41 · 95% CI 0.31 to 0.53Hazard ratio was estimated using a Cox Proportional Hazards model stratified by the number of lines of prior therapy, prior bortezomib and revised international staging system (R-ISS) at screening, with a covariate of treatment.
SecondaryComplete Response Rate (CRR)

CRR is defined as percentage of participants with a confirmed complete response or better.

Time frame:
Up to 73 months

Results for this outcome have not been posted.

SecondaryOverall Response Rate (ORR)

ORR is defined as percentage of participants with a confirmed partial response or better.

Time frame:
Up to 73 months

Results for this outcome have not been posted.

SecondaryClinical Benefit Rate (CBR)

CBR is defined as percentage of participants with a confirmed minimal response (MR) or better

Time frame:
Up to 73 months

Results for this outcome have not been posted.

SecondaryDuration of Response (DoR)

DOR is defined as time from first documented evidence of partial response or better until first documented progression or death, whichever occurs first.

Time frame:
Up to 73 months

Results for this outcome have not been posted.

SecondaryTime to Response (TTR)

TTR is defined as time from the date of randomization and the first documented evidence of response (PR or better) among participants who achieve partial response or better.

Time frame:
Up to 73 months

Results for this outcome have not been posted.

SecondaryTime to Progression (TTP)

TTP is defined as time from the date of randomization until the earliest date of documented date of disease progression or death, whichever occurs first.

Time frame:
Up to 73 months

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)

OS is defined as time from the date of randomization until the date of death due to any cause.

Time frame:
Up to 73 months

Results for this outcome have not been posted.

SecondaryProgression-free Survival on Subsequent Line of Therapy (PFS2)

Progression-free survival on subsequent line of therapy is defined as time from randomization to disease progression after initiation of new anti-myeloma therapy or death from any cause, whichever occurs first. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier.

Time frame:
Up to 73 months

Results for this outcome have not been posted.

SecondaryMinimal Residual Disease (MRD) Negativity Rate

Minimal Residual Disease (MRD) negativity rate is defined as the percentage of participants who are MRD negative status by next generation sequencing (NGS).

Time frame:
Up to 73 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.

Time frame:
Up to 73 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Clinically Significant Changes in Hematology Parameters

Blood samples will be collected for the analysis of hematology parameters.

Time frame:
Up to 73 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Clinically Significant Changes in Clinical Chemistry

Blood samples will be collected for the analysis of clinical chemistry parameters.

Time frame:
Up to 73 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Clinically Significant Changes in Urine Dipstick

Urine samples will be collected for the urine dipstick analysis.

Time frame:
Up to 73 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Abnormal Ocular Findings on Ophthalmic Examination
Time frame:
Up to 73 months

Results for this outcome have not been posted.

SecondaryPlasma Concentrations of Belantamab Mafodotin (Total Antibody) at Indicated Time Points

Blood samples will be collected for PK analysis of belantamab mafodotin.

Time frame:
Up to 73 months

Results for this outcome have not been posted.

SecondaryPlasma Concentrations of Belantamab Mafodotin (ADC) at Indicated Time Points

Blood samples will be collected for PK analysis of belantamab mafodotin.

Time frame:
Up to 73 months

Results for this outcome have not been posted.

SecondaryPlasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF) at Indicated Time Points

Blood samples will be collected for PK analysis of belantamab mafodotin.

Time frame:
Up to 73 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers.

Time frame:
Up to 73 months

Results for this outcome have not been posted.

SecondaryTiters of ADAs Against Belantamab Mafodotin

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be to be further tested in screening assay, and positive samples will be further to be characterized for antibody titers.

Time frame:
Up to 73 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)

The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE.

Time frame:
Up to 73 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in Health Related Quality of Life (HRQoL) as Measured by EuropeanOrganization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)

The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning \[PF\], role functioning \[RF\], cognitive functioning \[CF\], emotional functioning \[EF\] and social functioning \[SF\]), three symptom scales (fatigue, pain and nausea/vomiting \[N/V\]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss \[AL\] and financial difficulties \[FD\]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Up to 73 months

Results for this outcome have not been posted.

SecondaryChange From Baseline in HRQoL as Measured by EORTC IL52

The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score represents a high/healthy level of functioning.

Time frame:
Up to 73 months

Results for this outcome have not been posted.

Adverse events

Collected over All cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to approximately 41 months. The results presented are until the primary completion date. Additional results will be provided within a year of study completion.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)50/242 (20.7%)121/242 (50%)238/242 (98.3%)
Daratumumab + Bor + Dex77/246 (31.3%)90/246 (36.6%)239/246 (97.2%)
Most frequent serious events
Showing 10 of 163
Most frequent serious events
EventBelantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)Daratumumab + Bor + Dex
PneumoniaInfections and infestations27/24210/246
PyrexiaGeneral disorders12/2429/246
COVID-19Infections and infestations11/24210/246
COVID-19 pneumoniaInfections and infestations8/2428/246
ThrombocytopeniaBlood and lymphatic system disorders8/2424/246
Lower respiratory tract infectionInfections and infestations4/2420/246
AnaemiaBlood and lymphatic system disorders4/2423/246
SyncopeNervous system disorders4/2421/246
Orthostatic hypotensionVascular disorders4/2423/246
SepsisInfections and infestations3/2424/246
Most frequent other events
Showing 10 of 60
Most frequent other events
EventBelantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)Daratumumab + Bor + Dex
ThrombocytopeniaBlood and lymphatic system disorders167/242122/246
Vision blurredEye disorders160/24225/246
Dry eyeEye disorders123/24217/246
PhotophobiaEye disorders114/2426/246
Foreign body sensation in eyesEye disorders106/24210/246
Eye irritationEye disorders103/24213/246
Eye painEye disorders77/2428/246
DiarrhoeaGastrointestinal disorders76/24277/246
AnaemiaBlood and lymphatic system disorders45/24264/246
Peripheral sensory neuropathyNervous system disorders61/24251/246

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)Daratumumab + Bor + DexTotal
Mean64.5 ± 9.4763.6 ± 10.1164.0 ± 9.80
Sex: Female, Male
Sex: Female, Male(Participants)Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)Daratumumab + Bor + DexTotal
Female115107222
Male128144272
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex)Daratumumab + Bor + DexTotal
Hispanic or Latino304171
Not Hispanic or Latino213208421
Unknown or Not Reported022
08

Study locations

143 sites
  • GSK Investigational Site
    Yuma, Arizona 85364, United States
  • GSK Investigational Site
    Mission, Kansas 66205-2005, United States
  • GSK Investigational Site
    Denver, North Carolina 80128, United States
  • GSK Investigational Site
    Blue Ash, Ohio 45242-5665, United States
  • GSK Investigational Site
    Tyler, Texas 75702, United States
  • GSK Investigational Site
    Roanoke, Virginia 24014, United States
  • GSK Investigational Site
    Camperdown, New South Wales 2050, Australia
  • GSK Investigational Site
    Liverpool, New South Wales 2170, Australia
  • GSK Investigational Site
    Newcastle, New South Wales 2298, Australia
  • GSK Investigational Site
    St Leonards, New South Wales 2065, Australia
  • GSK Investigational Site
    Wollongong, New South Wales 2500, Australia
  • GSK Investigational Site
    Benowa, Queensland 4217, Australia
  • GSK Investigational Site
    Herston, Queensland 4029, Australia
  • GSK Investigational Site
    Ashford, South Australia 5037, Australia
  • GSK Investigational Site
    Box Hill, Victoria 3128, Australia
  • GSK Investigational Site
    Heidelberg, Victoria 3084, Australia
  • GSK Investigational Site
    Melbourne, Victoria 3004, Australia
  • GSK Investigational Site
    Murdoch, Western Australia 6150, Australia
  • GSK Investigational Site
    Nedlands, Western Australia 6009, Australia
  • GSK Investigational Site
    Jette, Brussels Capital 1090, Belgium
  • GSK Investigational Site
    Woluwé-Saint-Lambert, Brussels Capital 1200, Belgium
  • GSK Investigational Site
    Ghent, Oost-Vlaanderen 9000, Belgium
  • GSK Investigational Site
    Roeselare, 8800, Belgium
  • GSK Investigational Site
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • GSK Investigational Site
    Florianópolis, Santa Catarina 88020-210, Brazil
  • GSK Investigational Site
    Joinville, 89201-260, Brazil
  • GSK Investigational Site
    Natal, 59075-740, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 22775001, Brazil
  • GSK Investigational Site
    São Paulo, 04537-080, Brazil
  • GSK Investigational Site
    São Paulo, 05403-000, Brazil
  • GSK Investigational Site
    Edmonton, Alberta T6G 1Z2, Canada
  • GSK Investigational Site
    London, Ontario N6A 5W9, Canada
  • GSK Investigational Site
    Toronto, Ontario M4N 3M5, Canada
  • GSK Investigational Site
    Montreal, Quebec H4J 1C5, Canada
  • GSK Investigational Site
    Beijing, 100020, China
  • GSK Investigational Site
    Beijing, 100191, China
  • GSK Investigational Site
    Changchun, 130012, China
  • GSK Investigational Site
    Guangzhou, 510060, China
  • GSK Investigational Site
    Guangzhou, 510515, China
  • GSK Investigational Site
    Hangzhou, 310003, China
  • GSK Investigational Site
    Jinan, 250012, China
  • GSK Investigational Site
    Nanjing, 210008, China
  • GSK Investigational Site
    Shenyang, 110001, China
  • GSK Investigational Site
    Suzhou, 215006, China
  • GSK Investigational Site
    Tianjin, 300020, China
  • GSK Investigational Site
    Zhengzhou, 450052, China
  • GSK Investigational Site
    Brno, 625 00, Czechia
  • GSK Investigational Site
    Hradec Králové, 500 05, Czechia
  • GSK Investigational Site
    Ostrava, 708 52, Czechia
  • GSK Investigational Site
    Prague, 128 08, Czechia
  • GSK Investigational Site
    Amiens, 80054, France
  • GSK Investigational Site
    Caen, 14033, France
  • GSK Investigational Site
    Nice, 06200, France
  • GSK Investigational Site
    Paris, 75651, France
  • GSK Investigational Site
    Rennes, 35033, France
  • GSK Investigational Site
    Ulm, Baden-Wurttemberg 89081, Germany
  • GSK Investigational Site
    München, Bavaria 81377, Germany
  • GSK Investigational Site
    Würzburg, Bavaria 97080, Germany
  • GSK Investigational Site
    Düsseldorf, North Rhine-Westphalia 40225, Germany
  • GSK Investigational Site
    Jena, Thuringia 07747, Germany
  • GSK Investigational Site
    Cologne, 50937, Germany
  • GSK Investigational Site
    Alexandroupoli, East Macedonia and Thrace 681 00, Greece
  • GSK Investigational Site
    Athens, 11528, Greece
  • GSK Investigational Site
    Thessaloniki, 54007, Greece
  • GSK Investigational Site
    Jerusalem, 91120, Israel
  • GSK Investigational Site
    Kfar Saba, 44281, Israel
  • GSK Investigational Site
    Ramat Gan, 52621, Israel
  • GSK Investigational Site
    Tel Aviv, 64239, Israel
  • GSK Investigational Site
    Bergamo, 24127, Italy
  • GSK Investigational Site
    Bologna, 40138, Italy
  • GSK Investigational Site
    Brescia, 25123, Italy
  • GSK Investigational Site
    Catania, 95123, Italy
  • GSK Investigational Site
    Meldola FC, 47014, Italy
  • GSK Investigational Site
    Milan, 20133, Italy
  • GSK Investigational Site
    Ravenna, 48121, Italy
  • GSK Investigational Site
    Roma, 00168, Italy
  • GSK Investigational Site
    Siena, 53100, Italy
  • GSK Investigational Site
    Torino, 10126, Italy
  • GSK Investigational Site
    Aichi, 441-8570, Japan
  • GSK Investigational Site
    Aichi, 467-8602, Japan
  • GSK Investigational Site
    Aomori, 030-8553, Japan
  • GSK Investigational Site
    Ehime, 790-8524, Japan
  • GSK Investigational Site
    Fukuoka, 806-8501, Japan
  • GSK Investigational Site
    Fukuoka, 807-8555, Japan
  • GSK Investigational Site
    Fukuoka, 810-8563, Japan
  • GSK Investigational Site
    Fukuoka, 815-8555, Japan
  • GSK Investigational Site
    Gifu, 503-8502, Japan
  • GSK Investigational Site
    Gunma, 377-0280, Japan
  • GSK Investigational Site
    Hyōgo, 670-8540, Japan
  • GSK Investigational Site
    Kanagawa, 221-0855, Japan
  • GSK Investigational Site
    Kanagawa, 247-8533, Japan
  • GSK Investigational Site
    Kochi, 781-8555, Japan
  • GSK Investigational Site
    Nagano, 392-8510, Japan
  • GSK Investigational Site
    Okayama, 701-1192, Japan
  • GSK Investigational Site
    Osaka, 530-0012, Japan
  • GSK Investigational Site
    Osaka, 545-8586, Japan
  • GSK Investigational Site
    Shizuoka, 411-8777, Japan
  • GSK Investigational Site
    Dordrecht, South Holland 3318 AT, Netherlands
  • GSK Investigational Site
    Groningen, 9713 GZ, Netherlands
  • GSK Investigational Site
    Christchurch, 8011, New Zealand

Showing the first 100 of 143 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Zhang X, Xing X, Wang Z, Wang K, Hua Y, Zhang L, Dong X. Threshold Price of Belantamab for Relapsed/Refractory Multiple Myeloma in China: A Cost-Effectiveness Analysis. Pharmacoecon Open. 2026 Sep 11. doi: 10.1007/s41669-026-00681-8. Online ahead of print. PubMed 42726457 ↗
  • Mateos MV, Trudel S, Quach H, Robak P, Beksac M, Pour L, Hus M, Kim K, Zherebtsova V, Delimpasi S, Jelinek T, Ward C, Ho PJ, Vorobyev V, Pitombeira de Lacerda M, Aparecida-Martinez G, Spicka I, Radocha J, Cavo M, Cerchione C, Fu C, Suzuki K, Rogers R, Phillips-Jones A, Wang Z, Baig H, Wilkes J, Zhou XL, Lewis E, Eccersley L, Sule N, Paka P, Opalinska JB, Mukhopadhyay P, Hungria V, Dimopoulos MA. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. Blood Adv. 2025 Nov 25;9(22):5708-5719. doi: 10.1182/bloodadvances.2025016949. PubMed 40763276 ↗
  • Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Martinez GA, Sureda Balari A, Sandhu I, Cerchione C, Ganly P, Dimopoulos MA, Fu C, Garg M, Abdallah AO, Gatt ME, Oriol Rocafiguera A, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Ficek J, Mantero A, Pirooz N, Varghese S, Lee J, McKeown A, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Mukhopadhyay P, Nielsen J, Opalinska J, Mateos MV; DREAMM-7 study investigators. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Aug;26(8):1067-1080. doi: 10.1016/S1470-2045(25)00330-4. Epub 2025 Jul 15. PubMed 40680754 ↗
  • Hungria V, Hus M, Fu C, Zherebtsova V, Ward C, Ho PJ, Mikulski D, Muronova L, Cerchione C, Loubert A, Bunod L, M'Hari M, Pirooz N, Rogers R, Lin CP, Roy-Ghanta S, Opalinska JB, Purser M, McKeown A, McNamara S, Baig H, Eccersley L, Pompilus F, Mateos MV; DREAMM-7 trial study group. Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial. Lancet Haematol. 2025 Aug;12(8):e599-e610. doi: 10.1016/S2352-3026(25)00163-2. Epub 2025 Jul 15. PubMed 40680752 ↗
  • Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balari AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV; DREAMM-7 Investigators. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1. PubMed 38828933 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Oct 2023, 40 months.

Results were first posted in Oct 2024, 1 year after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 40 months is below that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

Completion moved once since we started tracking on Sep 25, 2026: Jun 2028 → Oct 2029, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2020
First posted
Jan 29, 2020
StartActual
May 7, 2020
Primary completionActual
Oct 2, 2023
CompletionEst.
Oct 8, 2029was Jun 2028
Results first posted
Oct 24, 2024
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Nov 13, 2026
Sites
82 sites added, 8 sites removed — first sites in Brazil, Canada, Czechia, France, Germany and 2 more
All 7 countries

Brazil, Canada, Czechia, France, Germany, New Zealand, United Kingdom

Show 82 added (10 Australia, 9 China, 7 Brazil, 7 United Kingdom, 6 Germany, 6 Italy, 5 France, 4 United States, 4 Canada, 4 Czechia, 4 New Zealand, 4 Spain, 3 Belgium, 3 Israel, 3 South Korea, 1 Greece, 1 Netherlands, 1 Russia)
  • GSK Investigational Site · Mission, United States
  • GSK Investigational Site · Denver, United States
  • GSK Investigational Site · Blue Ash, United States
  • GSK Investigational Site · Roanoke, United States
  • GSK Investigational Site · Camperdown, Australia
  • GSK Investigational Site · Newcastle, Australia
  • GSK Investigational Site · St Leonards, Australia
  • GSK Investigational Site · Herston, Australia
  • GSK Investigational Site · Ashford, Australia
  • GSK Investigational Site · Box Hill, Australia
  • GSK Investigational Site · Heidelberg, Australia
  • GSK Investigational Site · Melbourne, Australia
  • GSK Investigational Site · Murdoch, Australia
  • GSK Investigational Site · Nedlands, Australia
  • GSK Investigational Site · Jette, Belgium
  • GSK Investigational Site · Woluwé-Saint-Lambert, Belgium
  • GSK Investigational Site · Ghent, Belgium
  • GSK Investigational Site · Porto Alegre, Brazil
  • GSK Investigational Site · Florianópolis, Brazil
  • GSK Investigational Site · Joinville, Brazil
  • GSK Investigational Site · Natal, Brazil
  • GSK Investigational Site · Rio de Janeiro, Brazil
  • GSK Investigational Site · São Paulo, Brazil
  • GSK Investigational Site · São Paulo, Brazil
  • GSK Investigational Site · Edmonton, Canada
  • GSK Investigational Site · London, Canada
  • GSK Investigational Site · Toronto, Canada
  • GSK Investigational Site · Montreal, Canada
  • GSK Investigational Site · Beijing, China
  • GSK Investigational Site · Changchun, China
  • …and 52 more on the registry record
Show 8 removed
  • GSK Investigational Site · Denver, United States
  • GSK Investigational Site · Kansas City, United States
  • GSK Investigational Site · Fairfield, United States
  • GSK Investigational Site · Brussels, Belgium
  • GSK Investigational Site · Brussels, Belgium
  • GSK Investigational Site · Ghent, Belgium
  • GSK Investigational Site · Alexandroupoli, Greece
  • GSK Investigational Site · Dordrecht, Netherlands
Nov 13, 2026
Study completion
Jun 30, 2028→Oct 8, 2029
Nov 13, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42726457 ↗
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Posted results revised
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42726457 ↗
    82 sites added, 8 sites removed — first sites in Brazil, Canada, Czechia, France, Germany and 2 more
    All 7 countries

    Brazil, Canada, Czechia, France, Germany, New Zealand, United Kingdom

    Show 82 added (10 Australia, 9 China, 7 Brazil, 7 United Kingdom, 6 Germany, 6 Italy, 5 France, 4 United States, 4 Canada, 4 Czechia, 4 New Zealand, 4 Spain, 3 Belgium, 3 Israel, 3 South Korea, 1 Greece, 1 Netherlands, 1 Russia)
    • GSK Investigational Site · Mission, United States
    • GSK Investigational Site · Denver, United States
    • GSK Investigational Site · Blue Ash, United States
    • GSK Investigational Site · Roanoke, United States
    • GSK Investigational Site · Camperdown, Australia
    • GSK Investigational Site · Newcastle, Australia
    • GSK Investigational Site · St Leonards, Australia
    • GSK Investigational Site · Herston, Australia
    • GSK Investigational Site · Ashford, Australia
    • GSK Investigational Site · Box Hill, Australia
    • GSK Investigational Site · Heidelberg, Australia
    • GSK Investigational Site · Melbourne, Australia
    • GSK Investigational Site · Murdoch, Australia
    • GSK Investigational Site · Nedlands, Australia
    • GSK Investigational Site · Jette, Belgium
    • GSK Investigational Site · Woluwé-Saint-Lambert, Belgium
    • GSK Investigational Site · Ghent, Belgium
    • GSK Investigational Site · Porto Alegre, Brazil
    • GSK Investigational Site · Florianópolis, Brazil
    • GSK Investigational Site · Joinville, Brazil
    • GSK Investigational Site · Natal, Brazil
    • GSK Investigational Site · Rio de Janeiro, Brazil
    • GSK Investigational Site · São Paulo, Brazil
    • GSK Investigational Site · São Paulo, Brazil
    • GSK Investigational Site · Edmonton, Canada
    • GSK Investigational Site · London, Canada
    • GSK Investigational Site · Toronto, Canada
    • GSK Investigational Site · Montreal, Canada
    • GSK Investigational Site · Beijing, China
    • GSK Investigational Site · Changchun, China
    • …and 52 more on the registry record
    Show 8 removed
    • GSK Investigational Site · Denver, United States
    • GSK Investigational Site · Kansas City, United States
    • GSK Investigational Site · Fairfield, United States
    • GSK Investigational Site · Brussels, Belgium
    • GSK Investigational Site · Brussels, Belgium
    • GSK Investigational Site · Ghent, Belgium
    • GSK Investigational Site · Alexandroupoli, Greece
    • GSK Investigational Site · Dordrecht, Netherlands
    Study completion Jun 30, 2028→Oct 8, 2029
    + 3 other changes: identifiers, verification date and registry dates

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04246047
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 29, 2020
Start date
May 7, 2020
Primary completion
Oct 2, 2023
Completion
Oct 8, 2029 (estimated)
Results posted
Oct 24, 2024
Last update
Nov 13, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belantamab mafodotin

Start the discussion